HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
VJET
Catheter Precision, Inc.
There isn't enough reported data to score VJET yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
VJET Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
VJET's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
VJET PE Valuation
VJET has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
VJET Forward outlook
There aren't enough analyst estimates for VJET to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
VJET has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus VJET down 159%.
VJET Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$64,805.04 | +$44,178.96 |
| Q2 2023 | -$72,567.99 | +$91,782.01 |
| Q1 2023 | -$96,841.84 | +$164,408.16 |
| Q4 2022 | -$98,705.00 | +$372,495.00 |
| Q3 2020 | -$4,346,250.00 | +$7,528,750.00 |
VJET is still losing money, but far less than before: $64,805.04 per share over the past year, against $11,875,000.00 at its worst in late 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over VJET on profitability, with a higher operating margin.
VJET Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1M | +381% |
| Q1 2026 | $432K | +202% |
| Q4 2025 | $238K | +60% |
| Q3 2025 | $226K | +135% |
| Q2 2025 | $212K | +128% |
| Q1 2025 | $143K | +74% |
| Q4 2024 | $149K | +16% |
| Q3 2024 | $96K | -28% |
VJET's revenue is recovering but still below its 2019 peak: $1M last quarter, up 381% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -388% | +1822 points |
| Q1 2026 | -537% | +1963 points |
| Q4 2025 | -4143% | -2096 points |
| Q3 2025 | -1337% | +1641 points |
| Q2 2025 | -2210% | +711 points |
| Q1 2025 | -2500% | +690 points |
| Q4 2024 | -2048% | -19 points |
| Q3 2024 | -2978% | -926 points |
VJET's operating margin was −388% last quarter, up 1822 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over VJET on cash generation, producing positive trailing cash flow while its opponent burns cash.
VJET Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.9M | -$606K |
| Q1 2026 | -$2.8M | -$454K |
| Q4 2025 | -$1.5M | +$1.4M |
| Q3 2025 | -$2.2M | +$585K |
| Q2 2025 | -$2.3M | -$528K |
| Q1 2025 | -$2.3M | -$384K |
| Q4 2024 | -$2.9M | -$957K |
| Q3 2024 | -$2.8M | -$937K |
VJET has burned cash in almost every quarter: −$9M over the past year, against −$10M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over VJET on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
VJET Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +31% | +1.2K shares |
| 1 year | +41% | +1.5K shares |
| 3 years | +86633% | +5.2K shares |
VJET has 5,204 diluted shares, up 41% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
VJET Net Leverage
VJET's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
VJET Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.4 | Oversold |
| Stochastic | 0.7 | Oversold |
VJET's weekly RSI is 27 (oversold) and its Stochastic is 1 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
VJET PE vs Healthcare Sector
VJET has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
VJET Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.92 | 42% below |
| 20 week MA | $2.45 | 78% below |
| 50 week MA | $9.55 | 94% below |
| 100 week MA | $29.5 | 98% below |
| 200 week MA | $689.2 | 100% below |
VJET is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over VJET on returns for 2026, with the stronger performance.
VJET Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2,113,750.0 | $681,150.0 | -68% |
| 2021 | $681,150.0 | $164,350.0 | -76% |
| 2022 | $164,350.0 | $8,246.0 | -95% |
| 2023 | $8,246.0 | $767.6 | -91% |
| 2024 | $767.6 | $77.3 | -90% |
| 2025 | $77.3 | $16.8 | -78% |
| 2026 YTD | $16.8 | $0.53 | -97% |
VJET has finished every year since 2020 lower, and it's down 97% so far in 2026.